Why the CSL Limited share price just printed another record high

Shares in blood products and flu vaccine business CSL Limited (ASX: CSL) hit another record high of $232.69 today thanks to the falling Australian dollar making its U.S. dollar profits more valuable to Australian investors.

The US dollar is now buying close to A$1.40 on the back of the diverging interest rate spreads between the two countries with expectations that the Aussie dollar may have further to fall.

CSL has plenty going for it without the free kick of a weaker Australian dollar, as it was recently reported that the group plans to double the size of some of its US flu vaccine outputs via its Sequiris business in FY 2019 after gaining regulatory approval from the FDA.

Fresh from growing profits 29% in FY 2018, CSL is now forecasting profit growth of 10% – 14% in FY 2019, which is impressive considering it’s no tiddler.

In fact with a market value over $103 billion it’s only behind BHP Billiton Limited (ASX: BHP) and the Commonwealth Bank of Australia (ASX: CBA) in terms of market size. It might even overtake these two in the five years ahead if its earnings growth trajectory continues.

The Disruptors: 3 Revolutionary Aussie Companies to Back for 2018

We’re living in one of the most exciting times in investing history. Innovation and a booming culture of entrepreneurship are constantly creating new companies with the potential to make forward-thinking investors very rich. Now more than ever, one small, smart investment could make a huge difference to your wealth.

That’s why at The Motley Fool we’ve been scrutinizing the ASX to uncover the kinds of companies that we believe could turn into the next Atlassian.

We’ve found three exciting companies that we believe re poised to perform in the new year. Click here to uncover these ideas!

Motley Fool contributor Tom Richardson owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.